On June 19–20, 2023, Edinburgh, Scotland will be held the 17th Alzheimer's disease and Dementia Conference. At this conference, there will be scholars, delegates, and presenters from all around the world. This conference aims to increase public awareness.
Alzheimer’s disease
A degenerative neurological condition called Alzheimer's disease results in the death of brain cells and shrinkage of the brain. The most common cause of dementia, which is characterized by a persistent decline in mental, behavioral and social abilities and impairs a person's ability to function independently, is Alzheimer's disease. Alzheimer's disease affects over 5.8 million Americans aged 65 and older. Globally, between 60% and 70% of the 50 million dementia sufferers have Alzheimer's patients. Early symptoms of the disease include forgetting past events or experiences. The memory of a person with Alzheimer's disease is severely impaired and the condition worsens and the ability to perform basic functions is lost.
Dementia
A set of symptoms that considerably hinder memory, thinking, and interactive abilities are called dementia when they significantly disrupt everyday working. Although there is no one particular disease that causes dementia, many diseases can be. Although memory loss is a common symptom of dementia, there are many different reasons why it could occur. Memory loss alone does not indicate dementia, despite the fact that it is often one of the first signs of the disease. Although there are several additional causes of dementia, Alzheimer's disease is the most frequent one in older persons.
Past Affiliates
Claude M Wischik: Claude M Wischik holds the Chair in Old Age Psychiatry at the University of Aberdeen in Scotland, and is Executive Chairman of TauRx Pharmaceuticals. He studied medicine in Australia, completed his Ph.D. at the Laboratory of Molecular Biology in Cambridge, and also had higher psychiatric training in Cambridge. He was the first to identify Tau protein as the main constituent of the Alzheimer's tangle and developed the first Tau Aggregation Inhibitors. He has published 121 papers and holds 11 patent groups based on his work with over 40 individual patents.
Dr. Ian Martins: Dr. Ian Martins has been invited to join the editorial boards of several international journals and has been a reviewer for various journals (approx. 40). He was chosen to serve as the International Journal of Diabetes Research's Chief Editor (2014-2017). His H-index is 43 and he has STATS on Research Gate (23), Mendeley, and BIT Congress, Inc. (20). Over the course of the last 27 years, there have been 2900 citations to scientific research. Dr. Martins' publication statistics RG score is higher than 96% of the international researchers, according to Research Gate’s study, which is available on Google, Tweet, Facebook, and LinkedIn under the name Ian James Martins. Dr. Martins is now a SCIENTIST (Research Gate). He currently works for The Science Advisory Board as a Scientist (USA). Researcher and is a connecting researcher with ORCID. Contribution to biology is the peripheral synapse Abeta hypothesis and its relevance to organ suicide, diabetes, and Alzheimer's disease. Dr. Martins has received certificates of recognition at various international conferences, world congresses, and conferences regarding anti-aging, health, and disease.
Market Analysis
According to statistics, someone in the world acquires dementia every three seconds. According to the WHO, there were about 55 million dementia sufferers worldwide in 2021, and that figure is expected to rise every 20 years. Additionally, dementia is the sixth leading cause of death worldwide. The condition currently affects roughly 5.00 million individuals in India, with a potential increase to 14 million by 2050.
Elders must have a basic understanding of dementia, be aware of the disease's early symptoms, understand what can be done to prevent it, and be in the know because dementia is extremely frequent in seniors and the likelihood of developing it rises with age above 60.